Alberto Tozzi · The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19
Article1 min read·Published Jan 2020Older

The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2020 · 1 min read

In brief

In brief

This article explores G-quadruplex structures in viral genomes as potential therapeutic targets for COVID-19. It examines how G4 ligands and helicase inhibitors may reduce SARS-CoV-2 replication, and discusses repurposing FDA-approved antiviral drugs as a rapid treatment strategy.

Written by the GCMD Library team from the article.

Alberto Tozzi

G-Quadruplexes (G4s) are non-canonical secondary structures formed within guanine-rich regions of DNA or RNA. G4 sequences/structures have been detected in human and in viral genomes, including Coronaviruses Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-2. Here, we outline the existing evidence indicating that G4 ligands and inhibitors of SARS-CoV-2 helicase may exert some antiviral activity reducing viral replication and can represent a potential therapeutic approach to tackle the COVID-19 pandemic due to SARS-CoV-2 infection. We also discuss how repositioning of FDA-approved drugs against helicase activity of other viruses, could represent a rapid strategy to limit deaths associated with COVID-19 pandemic.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →